Alternative use of buprenorphine among people who use opioids in three U.S. Cities

References

• Dydyk AM, Jain NK, Gupta M. Opioid use disorder. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020.
   Google Scholar
• Ahmad FB, Rossen LM, Sutton P. Provisional Drug Overdose Death Counts. National Center for Health Statistics; 2020.
   Google Scholar
• Wilson N, Kariisa M, Seth P, Smith H, IV, Davis NL. Drug and opioid-involved overdose deaths – United States, 2017–2018. MMWR Morb Mortal Wkly Rep. 2020;69(11):290–297.
   PubMed Web of Science ®Google Scholar
• Velander JR. Suboxone: rationale, science, misconceptions. Ochsner J. 2018;18(1):23–29.
   PubMed Web of Science ®Google Scholar
• Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105(8):e55–e63.
   PubMed Web of Science ®Google Scholar
• Yokell MA, Zaller ND, Green TC, Rich JD. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Curr Drug Abuse Rev. 2011;4(1):28–41.
   PubMedGoogle Scholar
• Carroll JJ, Rich JD, Green TC. The more things change: buprenorphine/naloxone diversion continues while treatment remains inaccessible. J Addict Med. 2018;12(6):459–465.
   PubMed Web of Science ®Google Scholar
• Cicero TJ, Ellis MS, Chilcoat HD. Understanding the use of diverted buprenorphine. Drug Alcohol Depend. 2018;193:117–123.
   PubMed Web of Science ®Google Scholar
• Butler SF, Oyedele NK, Dailey Govoni T, Green JL. How motivations for using buprenorphine products differ from using opioid analgesics: evidence from an observational study of internet discussions among recreational users. JMIR Public Health Surveill. 2020;6(1):e16038.
   PubMedGoogle Scholar
• Chilcoat HD, Amick HR, Sherwood MR, Dunn KE. Buprenorphine in the United States: motives for abuse, misuse, and diversion. J Subst Abuse Treat. 2019;104:148–157.
   PubMed Web of Science ®Google Scholar
• Silverstein SM, Daniulaityte R, Miller SC, Martins SS, Carlson RG. On my own terms: motivations for self-treating opioid-use disorder with non-prescribed buprenorphine. Drug Alcohol Depend. 2020;210:107958.
   PubMed Web of Science ®Google Scholar
• Gwin Mitchell S, Kelly SM, Brown BS, et al. Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland. Am J Addict. 2009;18(5):346–355.
   PubMed Web of Science ®Google Scholar
• Richert T, Johnson B. Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden. Harm Reduct J. 2015;12:1.
   PubMed Web of Science ®Google Scholar
• Schulte B, Schmidt CS, Strada L, et al. Non-prescribed use of opioid substitution medication: patterns and trends in sub-populations of opioid users in Germany. Int J Drug Policy. 2016;29:57–65.
   PubMed Web of Science ®Google Scholar
• Glick JL, Christensen T, Park JN, McKenzie M, Green TC, Sherman SG. Stakeholder perspectives on implementing fentanyl drug checking: results from a multi-site study. Drug Alcohol Depend. 2019;194:527–532.
   PubMed Web of Science ®Google Scholar
• Sherman SG, Morales KB, Park JN, McKenzie M, Marshall BDL, Green TC. Acceptability of implementing community-based drug checking services for people who use drugs in three United States cities: Baltimore, Boston and Providence. Int J Drug Policy. 2019;68:46–53.
   PubMed Web of Science ®Google Scholar
• Goldsworthy RC, Schwartz NC, Mayhorn CB. Beyond abuse and exposure: framing the impact of prescription-medication sharing. Am J Public Health. 2008;98(6):1115–1121.
   PubMed Web of Science ®Google Scholar
• Beyene KA, Sheridan J, Aspden T. Prescription medication sharing: a systematic review of the literature. Am J Public Health. 2014;104(4):e15–e26.
   PubMed Web of Science ®Google Scholar
• Netherland J, Botsko M, Egan JE, et al. Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat. 2009;36(3):244–251.
   PubMed Web of Science ®Google Scholar
• Jaffe JH, O’Keeffe C. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend. 2003;70(2 Suppl):S3–S11.
   PubMedGoogle Scholar
• Schuman-Olivier Z, Connery H, Griffin ML, et al. Clinician beliefs and attitudes about buprenorphine/naloxone diversion. Am J Addict. 2013;22(6):574–580.
   PubMed Web of Science ®Google Scholar
• Priest KC. Commentary on Jin et al. (2020): regulatory and allocative policies inform access to opioid agonist therapy. Addiction. 2020;115(12):2255–2256.
   PubMed Web of Science ®Google Scholar
• Mravčík V, Janíková B, Drbohlavová B, Popov P, Pirona A. The complex relation between access to opioid agonist therapy and diversion of opioid medications: a case example of large-scale misuse of buprenorphine in the Czech Republic. Harm Reduct J. 2018;15(1):60.
   PubMedGoogle Scholar
• Bretteville-Jensen AL, Lillehagen M, Gjersing L, Andreas JB. Illicit use of opioid substitution drugs: prevalence, user characteristics, and the association with non-fatal overdoses. Drug Alcohol Depend. 2015;147:89–96.
   PubMed Web of Science ®Google Scholar
• Daniulaityte R, Nahhas RW, Silverstein S, et al. Patterns of non-prescribed buprenorphine and other opioid use among individuals with opioid use disorder: a latent class analysis. Drug Alcohol Depend. 2019;204:107574.
   PubMed Web of Science ®Google Scholar
• Carlson RG, Daniulaityte R, Silverstein SM, Nahhas RW, Martins SS. Unintentional drug overdose: is more frequent use of non-prescribed buprenorphine associated with lower risk of overdose? Int J Drug Policy. 2020;79:102722.
   PubMed Web of Science ®Google Scholar
• Krawczyk N, Mojtabai R, Stuart EA, et al. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services. Addiction. 2020;115(9):1683–1694.
   PubMed Web of Science ®Google Scholar
• Wightman RS, Perrone J, Scagos R, Krieger M, Marshall BDL, Nelson LS. Opioid overdose deaths with buprenorphine detected in postmortem toxicology: a retrospective analysis. J Med Toxicol. 2021;17(1):10–15.
   PubMed Web of Science ®Google Scholar
• Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert AS. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ. 2015;350:h2698.
   PubMed Web of Science ®Google Scholar
• Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ. 2017;356:j760.
   PubMed Web of Science ®Google Scholar
• Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 2012;125(1–2):8–18.
   PubMed Web of Science ®Google Scholar
• Allain F, Minogianis EA, Roberts DC, Samaha AN. How fast and how often: the pharmacokinetics of drug use are decisive in addiction. Neurosci Biobehav Rev. 2015;56:166–179.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang Y, Nielsen S, Kuhn L, Lam T. A systematic review of opioid overdose interventions delivered within emergency departments. Drug Alcohol Depend. 2020;213:108009.
   PubMed Web of Science ®Google Scholar
• Neale J, Stevenson C. Social and recovery capital amongst homeless hostel residents who use drugs and alcohol. Int J Drug Policy. 2015;26(5):475–483.
   PubMed Web of Science ®Google Scholar
• Pettersen H, Landheim A, Skeie I, et al. How social relationships influence substance use disorder recovery: a collaborative narrative study. Subst Abuse. 2019;13:1178221819833379.
   Web of Science ®Google Scholar
• Neale J, Tompkins CNE, Strang J. Qualitative exploration of relationships between peers in residential addiction treatment. Health Soc Care Community. 2018;26(1):e39–e46.
   PubMed Web of Science ®Google Scholar
• Weston S, Honor S, Best D. A tale of two towns: a comparative study exploring the possibilities and pitfalls of social capital among people seeking recovery from substance misuse. Subst Use Misuse. 2018;53(3):490–500.
   PubMed Web of Science ®Google Scholar
• McCarty D, Priest KC, Korthuis PT. Treatment and prevention of opioid use disorder: challenges and opportunities. Annu Rev Public Health. 2018;39:525–541.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS). 2017. Data on Substance Abuse Treatment Facilities. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2018.
   Google Scholar
• Hemsing N, Greaves L, Poole N, Schmidt R. Misuse of prescription opioid medication among women: a scoping review. Pain Res Manag. 2016;2016:1754195.
   PubMed Web of Science ®Google Scholar
• Koons AL, Rayl Greenberg M, Cannon RD, Beauchamp GA. Women and the experience of pain and opioid use disorder: a literature-based commentary. Clin Ther. 2018;40(2):190–196.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers and other drugs among women–United States, 1999–2010. MMWR Morb Mortal Wkly Rep. 2013;62:537–542.
   PubMed Web of Science ®Google Scholar
• VanHouten J, Rudd RA, Ballesteros MF, Mack KA. Drug overdose deaths among women aged 30–64 Years – United States, 1999–2017. MMWR Morb Mortal Wkly Rep. 2019;68(1):1–5.
   PubMed Web of Science ®Google Scholar
• Nguemeni Tiako MJ. Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid COVID-19. J Subst Abuse Treat. 2021;122:108214.
   PubMed Web of Science ®Google Scholar
• James K, Jordan A. The opioid crisis in black communities. J Law Med Ethics. 2018; 46(2):404–421.
   PubMed Web of Science ®Google Scholar
• Hansen HB, Roberts SK. Two tiers of biomedicalization: methadone, buprenorphine, and the racial politics of addiction treatment. Crit Perspect Addict. 2012;14:79–102.
   Google Scholar
• Olsen Y, Sharfstein JM. Confronting the stigma of opioid use disorder-and its treatment. JAMA. 2014;311(14):1393–1394.
   PubMed Web of Science ®Google Scholar
• Maclean JC, Saloner B. The effect of public insurance expansions on substance use disorder treatment: evidence from the Affordable Care Act. J Pol Anal Manage. 2019;38(2):366–393.
   PubMed Web of Science ®Google Scholar
• Dick AW, Pacula RL, Gordon AJ, et al. Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002–11. Health Aff (Millwood). 2015;34(6):1028–1034.
   PubMed Web of Science ®Google Scholar
• Shulman M, Wai JM, Nunes EV. Buprenorphine treatment for opioid use disorder: an overview. CNS Drugs. 2019;33(6):567–580.
   PubMed Web of Science ®Google Scholar
• Maclean JC, Wen H, Simon KI, Saloner B. Institutions for mental diseases medicaid waivers: impact on payments for substance use treatment facilities. Health Aff (Millwood). 2021;40(2):326–333.
   PubMed Web of Science ®Google Scholar